Skip to Content

Advanced Medical Solutions Group PLC AMS

Rating as of

Morningstar’s Analysis

Valuation
Currency in GBX
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Advanced Medical Solutions Continues to Invest in Moaty Products; No Change to Our FVE

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

While Advanced Medical Solutions has yet to release detailed half-year results, the preliminary data on favorable volume and operating leverage trends in the first half of 2021 is consistent with our assumptions for moderate resumption of surgical procedures, and we’re leaving our fair value estimate unchanged. We recognize the rise of the delta variant injects a new level of uncertainty that could depress surgical volume in the remainder of this year. However, we expect the impact of this latest wave will likely be highly localized. Either way, we do not think these near-term pandemic-driven fluctuations hold implications for underlying demand for the types of surgical procedures that utilize AMS’ products. Further, we’re pleased to see the firm continue to work on navigating the clinical trials and regulatory pathway for its more novel branded products. We view these differentiated products in AMS’ portfolio as key contributors to the firm’s narrow economic moat.

Read Full Analysis

Company Profile

Business Description

U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets the LiquiBand product line for tissue adhesion in acute settings, and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 57% of total revenue from branded products, with nonbranded contributing 43%.

Contact
Premier Park, 33 Road One, Winsford Industrial Estate
Winsford, Cheshire, CW7 3RT, United Kingdom
T +44 1606863500
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings
Fiscal Year End Dec 31, 2021
Stock Type
Employees 752

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.